MITF and melanoma: Melanoma dedifferentiation, a state characterized by a low level and activity of MITF, among other factors, has been connected to resistance to available therapies [137], whereas distinct trajectories between the IFN-γ and MITF signaling pathways are closely related to the resistance state of melanoma to immunotherapy [138].